Search Results46 results found
Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.
Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.
Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.
Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
RAPIVAB (peramivir injection) is a single-dose intravenous treatment for acute uncomplicated influenza, which was developed under contract with the US Government as part of pandemic preparedness efforts.
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).
Seqirus and Richter sign a license agreement for the commercialisation of a novel treatment for schizophrenia in Australia and New Zealand
Seqirus Pty Ltd (Seqirus) and Gedeon Richter Plc (Richter) today announced the signing of an exclusive license agreement to commercialise a novel antipsychotic in Australia and New Zealand.
Seqirus, a CSL Company created in July 2015 from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis, is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of control of influenza globally.
A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older.